Our portfolio companies are making headlines by changing the life of patients. Stay up-to-date on their latest news.
- DBJ Signs Contract with Newton Biocapital I Pricaf Privee SA, a Japanese-European Venture Capital Fund for Early Stage Pharmaceuticals
- EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities
- UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
- SEQUANA MEDICAL establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
- ACTICOR BIOTECH raises € 15.3 M in a Series B financing
- CHROMACURE S.A., a spin-off from the Université libre de Bruxelles (ULB),is launched with €17m committed equity investment to develop enhanced cancer therapies
- SYNERGIA raises €8.1 million in Series A
SEQUANA MEDICAL establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicenter of the Flanders healthcare hub, and the investment of €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders.
“Sequana Medical is entering a phase aimed at accelerated commercial growth and innovation. Moving our corporate headquarters to Ghent will allow us to benefit from Belgium’s attractive healthcare ecosystem and support for life sciences companies, as well as to strengthen our commercial ties within the EU”, said Ian Crosbie, Chief Executive Officer at Sequana Medical. “We are delighted to have secured such strong backing from leading local investors as well as from our existing shareholders. With this additional funding, we expect to drive towards profitability for our European commercial business, begin the North American pivotal study of the alfapump® for the treatment of liver recurrent and refractory ascites and commence first-in-human studies for our proprietary Direct Sodium Removal (“DSR”), a breakthrough therapy for the management of volume overload in heart failure.”
Rudy Dekeyser, Chairman of Sequana Medical, added, “Belgium is a key hub in the life sciences industry in Europe, known for its top scientific research and renowned investment funds. The establishment of its new headquarters in Flanders and attracting these prominent investors will enable Sequana Medical to further leverage its unique alfapump® technology and gain access to top talent.”
“We are very pleased to have attracted such a high quality company as Sequana Medical that matches so well with the Flanders’ healthcare ecosystem”, said Chris De Jonghe, Head of Life Sciences & Care at PMV. “It demonstrates our commitment to fund promising businesses and support them in their realisation of their growth ambitions.” Koen Van Loo, Managing Director at SFPI-FPIM added, “Sequana Medical will add significant value to our world-class ecosystem in life sciences and we are delighted to have joined a strong consortium of investors who have a shared vision about the Company’s exciting technology platform.” “Sequana Medical perfectly fits in our strategy to support innovative treatment solutions that will improve the quality of life for patients suffering from chronic diseases, such as liver disease and heart failure”, concluded Els Hubloux, Partner at Newton Biocapital Partners. “We are very pleased to welcome such a talented company within our Life Sciences Venture Capital portfolio.”
Sequana Medical has received CE Mark approval for its alfapump® system for liver refractory ascites and malignant ascites with proven safety, efficacy and quality of life benefits demonstrated in multiple clinical studies and over 650 implants. The Company is also developing alfapump® DSR, a convenient and fully implanted system for DSR, its proprietary therapy for the management of volume overload in heart failure. Pre-clinical proof of concept results of DSR therapy were recently presented at the Heart Failure Society of America’s annual conference.